AR117435A1 - Derivados de oxopiridina sustituidos - Google Patents

Derivados de oxopiridina sustituidos

Info

Publication number
AR117435A1
AR117435A1 ARP190103745A ARP190103745A AR117435A1 AR 117435 A1 AR117435 A1 AR 117435A1 AR P190103745 A ARP190103745 A AR P190103745A AR P190103745 A ARP190103745 A AR P190103745A AR 117435 A1 AR117435 A1 AR 117435A1
Authority
AR
Argentina
Prior art keywords
methyl
represents hydrogen
group
difluoromethyl
fluorine
Prior art date
Application number
ARP190103745A
Other languages
English (en)
Spanish (es)
Inventor
Lang Dieter Dr
Neubauer Thomas Dr
Ellerbrock Pascal Dr
Tersteegen Adrian Dr
Stefan Heitmeier
Meier Katharina Dr
Dr Hillisch Alexander Prof
Rhrig Susanne Dr
Gericke Kersten Matthias Dr
Stampfu Jan Dr
Essig Sebastian Dr
Sonja Anlauf
Schfer Martina Dr
Wang Vivian Dr
Zengqiang Zou
Xianghai Meng
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR117435A1 publication Critical patent/AR117435A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP190103745A 2018-12-21 2019-12-18 Derivados de oxopiridina sustituidos AR117435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21

Publications (1)

Publication Number Publication Date
AR117435A1 true AR117435A1 (es) 2021-08-04

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103745A AR117435A1 (es) 2018-12-21 2019-12-18 Derivados de oxopiridina sustituidos

Country Status (22)

Country Link
EP (1) EP3898633A1 (de)
JP (1) JP2022514303A (de)
KR (1) KR20210106504A (de)
CN (1) CN113474348A (de)
AR (1) AR117435A1 (de)
AU (1) AU2019407909B2 (de)
BR (1) BR112021009435A2 (de)
CA (1) CA3124220A1 (de)
CL (1) CL2021001613A1 (de)
CO (1) CO2021007908A2 (de)
CR (1) CR20210342A (de)
DO (1) DOP2021000128A (de)
EA (1) EA202191764A1 (de)
EC (1) ECSP21043895A (de)
IL (1) IL283990A (de)
JO (1) JOP20210161A1 (de)
MA (1) MA54521A (de)
MX (1) MX2021007508A (de)
PE (1) PE20211790A1 (de)
SG (1) SG11202104384PA (de)
TW (1) TW202039510A (de)
WO (1) WO2020127504A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220565T1 (hr) * 2018-03-15 2022-06-10 Bayer Aktiengesellschaft Postupak pripreme dva derivata 4-{[(2s)-2-{4-[5-klor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
CN117337170A (zh) 2021-03-09 2024-01-02 拜耳公司 包含(4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-二苯七蕃-74-甲酰胺的药物剂型
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN117015535A (zh) 2021-03-09 2023-11-07 拜耳公司 (4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-5二苯庚烷-74-甲酰胺的结晶形式
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JP6410819B2 (ja) 2013-07-23 2018-10-24 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体および第ＸＩａ因子／血漿としてのその使用
JP6368367B2 (ja) 2013-10-30 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体
ES2722425T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2712886T3 (es) * 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
JP6517925B2 (ja) 2014-09-24 2019-05-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたオキソピリジン誘導体
ES2694189T3 (es) 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
CA2979937A1 (en) 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (de) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate

Also Published As

Publication number Publication date
ECSP21043895A (es) 2021-07-30
TW202039510A (zh) 2020-11-01
CA3124220A1 (en) 2020-06-25
SG11202104384PA (en) 2021-05-28
IL283990A (en) 2021-07-29
DOP2021000128A (es) 2021-09-30
CL2021001613A1 (es) 2021-12-03
JOP20210161A1 (ar) 2023-01-30
EP3898633A1 (de) 2021-10-27
CN113474348A (zh) 2021-10-01
JP2022514303A (ja) 2022-02-10
AU2019407909A1 (en) 2021-05-27
BR112021009435A2 (pt) 2021-08-17
KR20210106504A (ko) 2021-08-30
CR20210342A (es) 2021-08-09
CO2021007908A2 (es) 2021-07-19
MX2021007508A (es) 2021-08-05
PE20211790A1 (es) 2021-09-09
AU2019407909B2 (en) 2023-05-25
EA202191764A1 (ru) 2021-10-22
MA54521A (fr) 2022-03-30
WO2020127504A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
AR117435A1 (es) Derivados de oxopiridina sustituidos
AR098492A1 (es) Derivados de purina
AR111776A1 (es) Heteroarilos inhibidores de las proteínas ras mutantes de g12c
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR105104A1 (es) Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR111241A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR096643A1 (es) Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo)
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR112099A1 (es) Imidazopirimidinas diazabicíclicas sustituidas y su uso
AR112907A1 (es) Pirazoles inhibidores de monoacilglicerol lipasa (magl)
AR100879A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR090678A1 (es) Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis
AR113888A1 (es) Derivados de indol macrocíclicos sustituidos
AR104856A1 (es) Derivados de difluorocetamida
AR103266A1 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados
AR101077A1 (es) Triterpenoides con actividad inhibidora de la maduración de hiv
AR103192A1 (es) Isotiazolamidas, procesos para su preparación y su uso como herbicidas y/o reguladores del crecimiento vegetal
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR107512A1 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
AR096424A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
AR121573A1 (es) Moduladores de nlrp3
AR109947A1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
AR115898A1 (es) 1,7-naftiridinas como inhibidores de cdk8/19